Friday, August 15, 2025 3:16:53 AM
Dennisdave, an update to my previous post.
Flipper found the SurVaxM Survive trial protocol that has some actual numbers. The IA was at 71 events and triggered in Jan 25. The final analysis (primary completion) is at 141 events. That may or may not have happened.
I still do not understand why Flipper thinks they need to publish final results by 1 year from the estimated primary completion. What we will see is the record being update to show the actual primary completion, and they have one year from then. Though more likely in a paper within about 6 months.
As a side note (as none of this matters to the -L MAA), his numbers do effect my rough estimates a bit. They now look better for SurVaxM, and I will change my opinion to neutral. Though I am still convinced the placebo arm will do well (MOS 20+ months). It is for that reason I think the trial could well fail.
Flipper found the SurVaxM Survive trial protocol that has some actual numbers. The IA was at 71 events and triggered in Jan 25. The final analysis (primary completion) is at 141 events. That may or may not have happened.
I still do not understand why Flipper thinks they need to publish final results by 1 year from the estimated primary completion. What we will see is the record being update to show the actual primary completion, and they have one year from then. Though more likely in a paper within about 6 months.
As a side note (as none of this matters to the -L MAA), his numbers do effect my rough estimates a bit. They now look better for SurVaxM, and I will change my opinion to neutral. Though I am still convinced the placebo arm will do well (MOS 20+ months). It is for that reason I think the trial could well fail.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
